Clinical Trials Browser

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT05501665 2024-10-17

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Phase 1/2 Recruiting

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03526900 2024-10-09

ATEZO-BRAIN

Phase 2 Completed

40 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05295212 2024-09-19

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Phase 2 Recruiting

120 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03689855 2024-07-30

RamAtezo-1

Phase 2 Completed

21 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04480372 2024-07-01

SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Phase 2 Completed

68 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT05284539 2024-06-07

Awesome

Phase 2 Recruiting

760 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04865250 2024-05-16

iReP

Phase 2 Recruiting

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05859217 2024-05-08

Cabatezo-1

Phase 2 Not yet recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03976518 2024-03-01

CHANCE

Phase 2 Completed

43 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03511391 2024-01-23

CHEERS

Phase 2 Completed

99 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT04099836 2023-12-26

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Phase 2 Terminated

7 enrolled 11 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02716038 2023-12-12

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

Phase 2 Completed

39 enrolled 8 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05259319 2023-10-17

IMMUNOs-SBRT

Phase 1 Unknown

92 enrolled

GenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT02994576 2023-09-29

PRINCEPS

Phase 2 Completed

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05418660 2023-09-18

I-STOP

Unknown

300 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06031597 2023-09-13

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Phase 3 Unknown

105 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Radiation Pneumonitis

NCT05935774 2023-08-25

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04639245 2023-08-03

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Phase 1/2 Terminated

1 enrolled 6 charts

BreastGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03102242 2023-05-24

Atezolizumab Immunotherapy in Patients With Advanced NSCLC

Phase 2 Completed

64 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03991403 2023-04-03

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Phase 3 Unknown

228 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03713944 2023-03-01